The tumor‐derived extracellular vesicles (TDEVs)‐tandem‐augmented chemoimmunotherapeutic strategy is utilized to prevent the immune surveillance caused by activating PD1/PD‐L1 pathway, proving to be effective in suppressing orthotopic tumors and minimizing pulmonary metastases. The gene discussed is CD274; the disease is neoplasm.